Andrew Brackmann's Stock Ratings

William Blair Analyst

Andrew Brackmann is an analyst at William Blair. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/18/2025

Overall Average Return

9.03%

Smart Score

Overall Average Return Percentile

58th

Number of Ratings

7

		Buy Now								Get Alert
03/17/2025	BFLY	Buy Now	Butterfly Network	$2.30	—	Andrew Brackmann38%	—	Initiates	→ Outperform	Get Alert
02/12/2025	TEM	Buy Now	Tempus AI	$62.10	—	Andrew Brackmann38%	—	Downgrade	Outperform → Market Perform	Get Alert
07/09/2024	TEM	Buy Now	Tempus AI	$62.10	—	Andrew Brackmann38%	—	Initiates	→ Outperform	Get Alert
02/14/2024	QDEL	Buy Now	QuidelOrtho	$33.46	—	Andrew Brackmann38%	—	Downgrade	Outperform → Market Perform	Get Alert
09/12/2023	SGHT	Buy Now	Sight Sciences	$3.55	—	Andrew Brackmann38%	—	Downgrade	Outperform → Market Perform	Get Alert
03/24/2023	MDXH	Buy Now	MDxHealth	$2.01	—	Andrew Brackmann38%	—	Initiates	→ Outperform	Get Alert
02/03/2022	SGHT	Buy Now	Sight Sciences	$3.55	—	Andrew Brackmann38%	—	Initiates	→ Outperform	Get Alert

Recent Analyst Stock Rating News

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and operational momentum.

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for sales and EPS reaffirmed.

Butterfly Network Is 'Pioneering Digital Ultrasound Market,' Analyst Says Undervalued Stock Could Rise With Growth Execution

Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential and a growing ultrasound market.

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit.

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

Guardant Reveal test receives expanded Medicare coverage for colorectal cancer recurrence monitoring, enhancing revenue potential and clinical adoption.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook